Beacon Trusteeship Discloses Encumbrance on Symbiotec Pharmalab Shares

Beacon Trusteeship Limited has filed a disclosure under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, regarding the encumbrance of 34,93,464 equity shares of Symbiotec Pharmalab Limited. This encumbrance, representing 5.44% of the total share capital, is in favor of Beacon Trusteeship Limited in its capacity as a debenture trustee. The encumbrance is linked to a debenture trust deed dated December 10, 2025, amended on December 18, 2025, concerning debentures issued by Satwani Holdings (India) Private Limited (SHIPL). The disclosure aligns with information previously provided in Symbiotec Pharmalab's Red Herring Prospectus.